

AMENDMENTS TO THE CLAIMS

Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A dry powder formulation for inhalation, comprising active particles and carrier particles for supporting the active particles, the formulation-further comprising magnesium stearate in an amount of at least 0.5% by weight of the formulation, wherein the particles of magnesium stearate are disposed on the surface of the carrier particles to provide a surface coverage of less than 10%-5% on the carrier particles.
2. (Cancelled)
3. (Currently Amended) The dry powder formulation according to claim 1, wherein the magnesium stearate is present in amounts an amount of from 0.5 to 2% by weight.
4. (Currently Amended) The dry powder formulation according to claim 1, wherein the magnesium stearate is present in amounts an amount of from 0.6 to 1% by weight.
5. (Previously Presented) The dry powder formulation according to claim 1, wherein the active particles comprise an active substance selected from the group consisting of beta-mimetics, anticholinergics, corticosteroids, leukotrienantagonists, phosphodiesterase inhibitors, PAF-inhibitors, potassium channel openers, analgesics, potency agents, macromolecules, pharmaceutically acceptable salts thereof and mixtures thereof.
6. (Previously Presented) The dry powder formulation according to claim 1, wherein the carrier particles comprise a carrier material selected from monosaccharides, disaccharides, sugar alcohols, polylactic acid, or mixtures thereof.
7. (Previously Presented) The dry powder formulation according to claim 6, wherein the carrier is lactose mono-hydrate.

8-11. (Cancelled)

12. (Previously Presented) The dry powder formulation according to claim 5, wherein the beta-mimetic is selected from the group consisting of Levalbuterol, Terbutalin, Reproterol, Salbutamol, Salmeterol, Formoterol, Fenoterol, Clenbuterol, Bambuterol, Tulobuterol, Broxaterol, Epinephrin, Isoprenaline and Hexoprenaline.

13. (Previously Presented) The dry powder formulation according to claim 5, wherein the anticholinergic is selected from the group consisting of Tiotropium, Ipratropium, Oxitropium and Glycopyrronium.

14. (Previously Presented) The dry powder formulation according to claim 5, wherein the corticosteroid is selected from the group consisting of Butixocart, Rofleponide, Budesonide, Ciclosenide, Mometasone, Fluticasone, Beclomethasone, Loteprednol and Triamcinolone.

15. (Previously Presented) The dry powder formulation according to claim 5, wherein the leukotrienantagonist is selected from the group consisting of Andolast, Iralukast, Pranlukast, Imitrodast, Seratrodast, Zileuton, Zafirlukast and Montelukast.

16. (Previously Presented) The dry powder formulation according to claim 5, wherein the phosphodiesterase-inhibitor is selected from Filaminast or Piclamilast.

17. (Previously Presented) The dry powder formulation according to claim 5, wherein the PAF-inhibitor is selected from the group consisting of Apafant, Forapafant and Israpafant.

18. (Previously Presented) The dry powder formulation according to claim 5, wherein the potassium channel opener is selected from Amiloride or Furosemide.

19. (Previously Presented) The dry powder formulation according to claim 5, wherein the analgesic is selected from the group consisting of Morphine, Fentanyl, Pentazocine, Buprenorphine, Pethidine, Tilidine, Methadone and Heroin.
20. (Previously Presented) The dry powder formulation according to claim 5, wherein the potency agent is selected from the group consisting of Sildenafil, Alprostadil and Phentolamine.
21. (Previously Presented) The dry powder formulation according to claim 5, wherein the macromolecule is selected from the group consisting of proteins, peptides, oligopeptides, polypeptides, polyamino acids, nucleic acids, polynucleotides, oligo-nucleotides and high molecular weight polysaccharides.
22. (Previously Presented) The dry powder formulation according to claim 6, wherein the monosaccharide or disaccharide is selected from the group consisting of glucose, lactose, lactose monohydrate, sucrose, trehalose and mixtures thereof.
23. (Previously Presented) The dry powder formulation according to claim 6, wherein the sugar alcohol is selected from mannitol, xylitol, or a mixture thereof.